RxDoctor Payments Data

Marcia Watson, DO

Pulmonary Disease · Philadelphia, PANPI 1447458153

Payments from drug & device makers

$1,797in general payments, 2019–2025

Across 81 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$433
  • GSK$402
  • AstraZeneca$372
  • Genentech USA, Inc.$144
  • Boehringer Ingelheim$119
  • Regeneron Healthcare Solutions, Inc.$79
  • plus $247 from 9 others

What the payments were for

  • Food & beverage$1,78299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,797 in reported general payments places this provider in the 55th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$52,050
Medicare patients
201
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab70$257,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter349$248,266
Dupixent SyringeDupilumab28$128,970
NucalaMepolizumab28$118,559
Fasenra PenBenralizumab15$83,909
XolairOmalizumab23$76,563
FasenraBenralizumab13$73,294
Breo ElliptaFluticasone/Vilanterol102$56,616
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr81$43,129
Spiriva RespimatTiotropium Bromide63$38,779
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$36,237
Albuterol Sulfate HfaAlbuterol Sulfate345$12,919
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$11,002
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate40$10,392
Fluticasone-SalmeterolFluticasone Propion/Salmeterol71$9,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$402$476,942587 claims
AstraZenecaFasenra, Breztri Aerosphere, Symbicort$372$118,615107 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$119$49,78183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →